FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385364251> ?p ?o ?g. }

• W4385364251 endingPage "22" @default.
• W4385364251 startingPage "16" @default.
• W4385364251 abstract "Background Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major preventable cause of stroke and hospitalizations, with an estimate prevalence of 2.5%. Current guidelines recommend oral anticoagulant therapy for AF patients at moderate or high risk of stroke. However, despite the effectiveness of oral anticoagulants in stroke prevention, such a therapy remains broadly underused. Purpose The aim of this study was to evaluate Vitamin K Antagonists (VKAs) treatment in patients with Non Vascular AF (NVAF) in everyday clinical practice in light of current treatment guidelines, and to analyze the costs associated with patient management. Methods This retrospective observational study was performed utilizing several databases of the Local Health Authority 9 of Treviso, Italy, from January 1, 2010 to December 31, 2013. The cohort of patients affected by NVAF was identified on the basis of Hospital Discharge Records of the years 2010-2013, considering ICD9-CM diagnosis codes for atrial fibrillation and atrial flutter. After the first diagnosis of NVAF, patients have been stratified according to the individual stroke risk (CHA2DS2-VASc score), therapeutic treatment with VKA and achievement of anticoagulation control (Time in Therapeutic Range, TTR). The cost analysis for the year 2013 was performed for naïve and prevalent patients, separately; for naïve patients, costs in the year 2014 were also evaluated, so that data available for each patient referred to a minimum period of 12 months. Results The cohort of patients with NVAF identified for the years 2010-2013 comprised 4855 patients, of which 53% were treated with oral VKAs. This percentage decreases to 29.6% considering only patients with at least 6 continuative months of therapy and at least 8 INR (International Normalized Ratio) controls. Furthermore, only 31% of VKA-treated patients reached the therapeutic target (TTR ≥65%). The cost analysis showed that naïve patients cost 1.4 times more than prevalent patients. In particular, clinician visits and hospitalizations represent the key cost drivers. On the other hand, costs for anticoagulant and cardiovascular therapies are the lowest expense items, although also in this case they are higher for incident compared to prevalent patients. Conclusions Management of NVAF patients treated with VKA is challenging, because of the high rate of treatment disaffection and discontinuation. In treated patients, TTR amelioration appears to be a crucial point for effectively preventing thromboembolic risk and reducing rehospitalization costs due to cardiovascular events." @default.
• W4385364251 created "2023-07-29" @default.
• W4385364251 creator A5004398505 @default.
• W4385364251 creator A5014376004 @default.
• W4385364251 creator A5019998926 @default.
• W4385364251 creator A5020026322 @default.
• W4385364251 creator A5029940869 @default.
• W4385364251 creator A5039798710 @default.
• W4385364251 creator A5044432648 @default.
• W4385364251 creator A5048562308 @default.
• W4385364251 date "2018-02-16" @default.
• W4385364251 modified "2023-09-29" @default.
• W4385364251 title "Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice Analysis" @default.
• W4385364251 doi "https://doi.org/10.33393/grhta.2016.403" @default.
• W4385364251 hasPublicationYear "2018" @default.
• W4385364251 type Work @default.
• W4385364251 citedByCount "0" @default.
• W4385364251 crossrefType "journal-article" @default.
• W4385364251 hasAuthorship W4385364251A5004398505 @default.
• W4385364251 hasAuthorship W4385364251A5014376004 @default.
• W4385364251 hasAuthorship W4385364251A5019998926 @default.
• W4385364251 hasAuthorship W4385364251A5020026322 @default.
• W4385364251 hasAuthorship W4385364251A5029940869 @default.
• W4385364251 hasAuthorship W4385364251A5039798710 @default.
• W4385364251 hasAuthorship W4385364251A5044432648 @default.
• W4385364251 hasAuthorship W4385364251A5048562308 @default.
• W4385364251 hasBestOaLocation W43853642511 @default.
• W4385364251 hasConcept C126322002 @default.
• W4385364251 hasConcept C127413603 @default.
• W4385364251 hasConcept C167135981 @default.
• W4385364251 hasConcept C177713679 @default.
• W4385364251 hasConcept C187212893 @default.
• W4385364251 hasConcept C194828623 @default.
• W4385364251 hasConcept C201903717 @default.
• W4385364251 hasConcept C23131810 @default.
• W4385364251 hasConcept C2778292772 @default.
• W4385364251 hasConcept C2779161974 @default.
• W4385364251 hasConcept C2780645631 @default.
• W4385364251 hasConcept C71924100 @default.
• W4385364251 hasConcept C72563966 @default.
• W4385364251 hasConcept C78519656 @default.
• W4385364251 hasConceptScore W4385364251C126322002 @default.
• W4385364251 hasConceptScore W4385364251C127413603 @default.
• W4385364251 hasConceptScore W4385364251C167135981 @default.
• W4385364251 hasConceptScore W4385364251C177713679 @default.
• W4385364251 hasConceptScore W4385364251C187212893 @default.
• W4385364251 hasConceptScore W4385364251C194828623 @default.
• W4385364251 hasConceptScore W4385364251C201903717 @default.
• W4385364251 hasConceptScore W4385364251C23131810 @default.
• W4385364251 hasConceptScore W4385364251C2778292772 @default.
• W4385364251 hasConceptScore W4385364251C2779161974 @default.
• W4385364251 hasConceptScore W4385364251C2780645631 @default.
• W4385364251 hasConceptScore W4385364251C71924100 @default.
• W4385364251 hasConceptScore W4385364251C72563966 @default.
• W4385364251 hasConceptScore W4385364251C78519656 @default.
• W4385364251 hasIssue "1" @default.
• W4385364251 hasLocation W43853642511 @default.
• W4385364251 hasOpenAccess W4385364251 @default.
• W4385364251 hasPrimaryLocation W43853642511 @default.
• W4385364251 hasRelatedWork W1567185503 @default.
• W4385364251 hasRelatedWork W2062848816 @default.
• W4385364251 hasRelatedWork W2398888823 @default.
• W4385364251 hasRelatedWork W2409400224 @default.
• W4385364251 hasRelatedWork W2460869168 @default.
• W4385364251 hasRelatedWork W253329954 @default.
• W4385364251 hasRelatedWork W2790839432 @default.
• W4385364251 hasRelatedWork W2976401173 @default.
• W4385364251 hasRelatedWork W4243134933 @default.
• W4385364251 hasRelatedWork W3158562858 @default.
• W4385364251 hasVolume "3" @default.
• W4385364251 isParatext "false" @default.
• W4385364251 isRetracted "false" @default.
• W4385364251 workType "article" @default.